BrightPath Biotherapeutics Overview

  • Founded
  • 2003

  • Status
  • Public

  • Employees
  • 44

  • Stock Symbol
  • 4594

Stock Symbol
  • Share Price
  • $1.34

  • (As of Wednesday Closing)

BrightPath Biotherapeutics General Information


BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.

Contact Information

Formerly Known As
GreenPeptide Co., Ltd., GreenPeptide
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • Fukuoka Bio Incubation Center, 1-1 Hyakunenkoen
  • Kurume-shi
  • Fukuoka, 839-0864
  • Japan
+81 0000-00-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BrightPath Biotherapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.34 $1.32 $0.41 - $1.84 $84.1M 62.9M 7.2M -$0.22

BrightPath Biotherapeutics Financials Summary

In Thousands,
TTM 31-Dec-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 31,380 23,499 54,267 51,491
Revenue 155 137 24 104
EBITDA (12,874) (15,566) (16,531)
Net Income (12,410) (13,211) (16,217) (17,086)
Total Assets 15,062 22,706 33,988 32,151
Total Debt 0 717 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BrightPath Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BrightPath Biotherapeutics‘s full profile, request access.

Request a free trial

BrightPath Biotherapeutics Patents

BrightPath Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4140501-A1 Improved peptide vaccine Pending 23-Apr-2020 000000000
EP-4006148-A1 Method for producing cell population containing car-expressing immune cells Pending 31-Jul-2019 000000000
US-20220265714-A1 Method for producing cell population containing car-expressing immune cells Pending 31-Jul-2019 000000000
US-20220313803-A1 Novel neoantigens and cancer immunotherapy using same Pending 07-Jan-2019 000000000
JP-6142384-B1 Reagent for antibody test Active 14-Sep-2016 G01N33/53
To view BrightPath Biotherapeutics’s complete patent history, request access »

BrightPath Biotherapeutics Executive Team (7)

Name Title Board Seat Contact Info
Kenichi Nagai President & Chief Executive Officer
Teruhiko Sakai Chief Financial Officer & Director
Yutaka Waki Chief Operating Officer
Kyogo Ito Founding Scientist
You’re viewing 4 of 7 executive team members. Get the full list »

BrightPath Biotherapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BrightPath Biotherapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies











To view BrightPath Biotherapeutics’s complete esg history, request access »